首页> 美国卫生研究院文献>Bioengineering >Initial Clinical Experience with Ahmed Valve in Romania: Five-Year Patient Follow-Up and Outcomes
【2h】

Initial Clinical Experience with Ahmed Valve in Romania: Five-Year Patient Follow-Up and Outcomes

机译:罗马尼亚 Ahmed Valve 的初步临床经验:五年患者随访和结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Glaucoma is a leading cause of irreversible blindness worldwide and is particularly challenging to treat in its refractory forms. The Ahmed valve offers a potential solution for these difficult cases. This research aims to assess the initial clinical experience with Ahmed valve implantation in Romania, evaluating its effectiveness, associated complications, and overall patient outcomes over a five-year period. Methods: We conducted a prospective study on 50 patients who underwent Ahmed valve implantation due to various types of glaucoma. Patients were monitored at several intervals, up to five years post-surgery. Intraocular pressure and visual acuity were the primary measures of success. Results: On average, patients maintained the intraocular pressure within the targeted range, with the mean intraocular pressure being 17 mmHg 5 years post-surgery. Success, defined as maintaining target intraocular pressure without additional surgery, was achieved in 82% at 1 year, 68% at 3 years, and 60% after 5 years postoperative. Conclusion: Ahmed valve implantation is a viable treatment option for refractory glaucoma, demonstrating significant intraocular pressure reduction and manageable complication rates over a five-year follow-up period. Future research should focus on long-term outcomes and optimization of surgical techniques to further reduce complication rates and improve patient quality of life.
机译:背景: 青光眼是全球不可逆失明的主要原因,难治性形式的治疗尤其具有挑战性。Ahmed 阀为这些困难情况提供了潜在的解决方案。本研究旨在评估罗马尼亚 Ahmed 瓣膜植入术的初步临床经验,评估其有效性、相关并发症和五年内患者的总体预后。方法: 我们对 50 例因各种类型青光眼而接受 Ahmed 瓣膜植入术的患者进行了前瞻性研究。患者在手术后长达 5 年内多次接受监测。眼压和视力是衡量成功的主要指标。结果: 平均而言,患者眼压维持在目标范围内,术后 5 年平均眼压为 17 mmHg。成功定义为无需额外手术即可维持目标眼压,术后 1 年时达到 82%,3 年时达到 68%,术后 5 年达到 60%。结论: Ahmed 瓣膜植入术是难治性青光眼的可行治疗选择,在五年随访期间表现出显着的眼压降低和可控的并发症发生率。未来的研究应侧重于长期结果和手术技术的优化,以进一步降低并发症发生率并提高患者的生活质量。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号